Stay updated with breaking news from Endogenous Cannabinoids. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Palmitoylethanolamide (PEA) is a safer and more pervasive therapeutic alternative to cannabidiol, say the authors of the Gencor Pacific-commissioned review, ‘Palmitoylethanolamide: A Potential Alternative to Cannabidiol.’
Palmitoylethanolamide (PEA) is a safer and more pervasive therapeutic alternative to cannabidiol, say the authors of the Gencor Pacific-commissioned review, ‘Palmitoylethanolamide: A Potential Alternative to Cannabidiol.’
VANCOUVER, BC, Jan. 19, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), today announced that executives of the Company will speak at the 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe ("CDP Europe"). CDP Europe will be held virtually from January 19-21, 2021. Michael Woudenberg - Vice President, Chemistry, Manufacturing & Controls, Karen Long - Senior...